2/24
07:01 pm
lly
Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.
Low
Report
Eli Lilly and Company (LLY) is now covered by Royal Bank Of Canada. They set an "outperform" rating on the stock.
2/24
12:53 pm
lly
Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]
Low
Report
Novo downgraded at J.P. Morgan as next-gen obesity drug trails Lilly's Zepbound [Seeking Alpha]
2/24
12:16 am
lly
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]
Low
Report
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs [Yahoo! Finance Canada]
2/23
10:25 am
lly
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]
Low
Report
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen [MSNBC.com]
2/23
09:02 am
lly
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]
Low
Report
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen [CNBC]
2/23
09:00 am
lly
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Low
Report
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
2/23
06:13 am
lly
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial [MSNBC.com]
Low
Report
Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial [MSNBC.com]
2/21
12:38 pm
lly
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo [Yahoo! Finance]
Medium
Report
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo [Yahoo! Finance]
2/21
06:31 am
lly
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Medium
Report
Eli Lilly and Company (NYSE:LLY) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
2/20
09:43 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Berenberg Bank from $950.00 to $1,050.00. They now have a "hold" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Berenberg Bank from $950.00 to $1,050.00. They now have a "hold" rating on the stock.
2/20
06:00 am
lly
Out of nowhere, Canada became poorer than Alabama. How is that possible? [Globe and Mail, The (Toronto, Canada)]
Low
Report
Out of nowhere, Canada became poorer than Alabama. How is that possible? [Globe and Mail, The (Toronto, Canada)]
2/19
08:01 pm
lly
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
2/19
07:46 pm
lly
Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity [Yahoo! Finance]
Low
Report
Eli Lilly (LLY) Announces Positive Phase 3b Results for Taltz and Zepbound Combination Treatment in Psoriasis and Obesity [Yahoo! Finance]
2/19
12:15 pm
lly
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Low
Report
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
2/18
01:11 pm
lly
Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects [Seeking Alpha]
Low
Report
Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects [Seeking Alpha]
2/18
10:22 am
lly
Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns [Yahoo! Finance]
Low
Report
Eli Lilly and Company (LLY) Gains as Medicare Expansion of GLP-1 Weight Loss Drugs Eases Pricing Concerns [Yahoo! Finance]
2/18
09:41 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Daiwa Securities Group Inc. from $1,230.00 to $1,250.00. They now have a "buy" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Daiwa Securities Group Inc. from $1,230.00 to $1,250.00. They now have a "buy" rating on the stock.
2/18
07:29 am
lly
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study [CNBC]
Low
Report
Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study [CNBC]
2/18
06:45 am
lly
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
Low
Report
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight
2/17
08:00 am
lly
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
Low
Report
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
2/16
10:00 am
lly
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
Low
Report
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
2/16
08:10 am
lly
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company [Yahoo! Finance]
Low
Report
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company [Yahoo! Finance]
2/16
08:00 am
lly
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
Low
Report
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company
2/16
06:45 am
lly
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Low
Report
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
2/13
09:43 am
lly
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Argus from $930.00 to $1,200.00. They now have a "buy" rating on the stock.
Low
Report
Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at Argus from $930.00 to $1,200.00. They now have a "buy" rating on the stock.